Bristol Myers Squibb

Bristol Myers Squibb is an American multinational biopharmaceutical company headquartered in Princeton, New Jersey. It researches, develops, manufactures, and commercializes prescription medicines for serious and life-threatening conditions. Its principal therapeutic areas include oncology, hematology, immunology, cardiovascular disease, and selected neurological and psychiatric disorders. The company sells medicines globally, although the United States remains its largest market. BMS was created in 1989 through the merger of Bristol-Myers and Squibb. The two predecessor businesses had different but complementary histories. Squibb was founded in Brooklyn in 1858 by Edward Robinson Squibb, whose work emphasized pharmaceutical purity, quality control, and scientific standards. The company became an important supplier of medicines and medical supplies during the American Civil War and later built a major penicillin facility in New Brunswick, New Jersey. Bristol-Myers began in 1887, when William McLaren Bristol and John Ripley Myers acquired the Clinton Pharmaceutical Company in Clinton, New York. It became known for consumer and prescription products including Sal Hepatica, Ipana toothpaste, antibiotics, and later a range of household and personal-care brands. For much of the twentieth century, both businesses operated as diversified healthcare companies. Bristol-Myers expanded into consumer products, hair care, household goods, and over-the-counter medicines, while Squibb developed a strong prescription and hospital-medicine presence. The 1989 merger combined their research, manufacturing, commercial, and international capabilities. During the 2000s and 2010s, BMS progressively shifted away from the diversified consumer-products model and toward a focused specialty-biopharmaceutical strategy. It divested or separated several consumer businesses, reduced and consolidated manufacturing capacity, and concentrated investment on innovative medicines and biologic therapies. The company's modern portfolio was shaped by internal research, licensing, collaborations, and acquisitions. Important additions included Medarex, which strengthened antibody and immuno-oncology capabilities; Celgene, which brought major hematology and oncology products; MyoKardia, which added cardiovascular medicine; Turning Point Therapeutics and Mirati Therapeutics, which expanded targeted oncology; and Karuna Therapeutics, which provided the investigational KarXT program for schizophrenia. The Celgene transaction, completed after a shareholder vote and regulatory remedies that included the divestiture of Otezla to Amgen, was one of the largest strategic transformations in the company's history. BMS's major marketed medicines include Eliquis, an anticoagulant developed with Pfizer; Opdivo, an immune checkpoint inhibitor; Revlimid, Pomalyst, and Abraxane-related oncology and hematology products associated with the Celgene portfolio; Orencia for autoimmune disease; Yervoy for cancer; and Reblozyl for anemia associated with beta thalassemia and myelodysplastic syndromes. The company also commercializes cell therapies and other advanced treatments. In 2024, the U.S. Food and Drug Administration approved Cobenfy, a new type of schizophrenia treatment based on muscarinic receptor activity rather than the traditional dopamine-centered approach. BMS maintains research and development operations in the United States and internationally, including sites in New Jersey, Massachusetts, California, Belgium, Spain, Japan, India, and the United Kingdom. Its stated positioning is that of a research-based biopharmaceutical company addressing severe unmet medical needs. The company remains active and publicly traded on the New York Stock Exchange under the symbol BMY.

Bristol Myers Squibb combines the histories of two American pharmaceutical companies. Edward Robinson Squibb established Squibb in Brooklyn in 1858. He promoted unusually strict standards for pharmaceutical purity and published scientific material after concluding that prevailing industry standards were inadequate. Squibb supplied medical materials to the Union Army during the Civil War, including medicines, anesthetics, quinine, and portable medical kits. In 1944, the company opened a major penicillin plant in New Brunswick, New Jersey, helping support wartime production. Bristol-Myers originated in Clinton, New York, where William McLaren Bristol and John Ripley Myers acquired the Clinton Pharmaceutical Company in 1887. The business adopted the Bristol, Myers and Company name in 1898 and became the Bristol-Myers Corporation after Myers's death. Its early nationally recognized products included Sal Hepatica, a laxative mineral salt, and Ipana toothpaste. Over time, the company diversified into prescription medicines, antibiotics, consumer healthcare, hair products, and household products. During World War II, its acquisition of Cheplin Biological Laboratories enabled the production of penicillin for Allied forces. The two companies remained separate competitors for much of the twentieth century. Their businesses eventually converged around research, manufacturing, and commercialization of prescription medicines, and they merged in 1989 to form Bristol-Myers Squibb. The merger created a large diversified healthcare company with consumer, hospital, and prescription businesses. The combined company received the U.S. National Medal of Technology in 1999 for pharmaceutical research, development, and clinical-trial innovation. The early 2000s exposed challenges in the company's commercial and governance model. In 2006, federal investigators searched company offices in connection with allegations involving Plavix distribution, channel stuffing, and generic competition. A court-appointed monitor recommended the removal of CEO Peter Dolan, and Dolan stepped down. The deferred-prosecution arrangement ended in 2007 without further Department of Justice action on the matters covered by that agreement. From 2007 onward, BMS pursued a deliberate transformation into a specialty biopharmaceutical company. It reduced exposure to consumer products, separated Mead Johnson Nutrition, sold or divested additional consumer brands, closed or consolidated manufacturing facilities, and introduced productivity and workforce-reduction programs. Acquisitions and partnerships became central to the strategy. Medarex strengthened antibody research; ZymoGenetics added development assets; Inhibitex expanded hepatitis C research; Amylin temporarily broadened diabetes activities; and later purchases added capabilities in immuno-oncology, autoimmune disease, cardiovascular medicine, and targeted cancer therapy. The approval of Opdivo in 2014 marked a major point in BMS's rise as an immuno-oncology company. The medicine, a PD-1 inhibitor, became part of a broader cancer portfolio that also included Yervoy and later combination-based treatment approaches. During the following decade, BMS expanded through collaborations and acquisitions including Flexus Biosciences, Cardioxyl, Padlock Therapeutics, Cormorant Pharmaceuticals, and IFM Therapeutics. The 2019 Celgene acquisition was a defining corporate event. It significantly enlarged BMS's oncology and hematology portfolio and added products such as Revlimid and Pomalyst. The transaction faced opposition from some investors and required the divestiture of Otezla to Amgen to obtain regulatory clearance. Subsequent acquisitions continued to diversify the company: MyoKardia added cardiovascular medicine; Forbius and other transactions expanded development capabilities; Turning Point and Mirati strengthened targeted oncology; and Karuna added a novel neuroscience and psychiatric program. In the 2020s, BMS also invested in advanced manufacturing, artificial-intelligence-supported clinical research, cell therapy production, and external innovation. Partnerships with Cellares and Owkin reflected efforts to improve manufacturing and trial design. The FDA approval of Cobenfy in 2024 extended the company into schizophrenia treatment and demonstrated the breadth of its post-Celgene portfolio. BMS now operates as a global research-based biopharmaceutical company with major activities in oncology, hematology, immunology, cardiovascular disease, and selected neuroscience indications.

1. 2024BMS expanded into schizophrenia treatment

   The FDA approved Cobenfy, bringing a novel muscarinic approach to the company's commercial portfolio.

   Source
2. 2022BMS acquired Turning Point Therapeutics

   The acquisition expanded targeted oncology research, including repotrectinib.

   Source
3. 2020MyoKardia became part of BMS

   The acquisition added mavacamten and strengthened BMS's cardiovascular pipeline.

   Source
4. 2019BMS announced the Celgene acquisition

   The transaction reshaped the company around oncology and hematology and was completed with a required Otezla divestiture.

   Source
5. 2014Opdivo received FDA approval

   Nivolumab was approved for certain patients with advanced melanoma, establishing a major immuno-oncology franchise.

   Source
6. 2006CEO Peter Dolan stepped down

   Dolan left the chief executive role during the Plavix distribution and generic-competition controversy.

   Source
7. 1999BMS received the National Medal of Technology

   The company was recognized for pharmaceutical research, development, and clinical-trial innovation.

   Source
8. 1989Bristol-Myers and Squibb merged

   The merger created Bristol-Myers Squibb.

   Source
9. 1944Squibb opened a major penicillin plant

   The New Brunswick facility became an important site for large-scale penicillin production.

   Source
10. 1887Bristol and Myers acquired Clinton Pharmaceutical

    William McLaren Bristol and John Ripley Myers acquired the Clinton, New York pharmaceutical company that developed into Bristol-Myers.

    Source
11. 1858Squibb was established

    Edward Robinson Squibb founded the pharmaceutical business that became one of BMS's two historical predecessors.

    Source

Research-based biopharmaceutical company focused on serious diseases and high unmet medical need.

• EliquisCardiovascular medicine

  Apixaban is an oral anticoagulant developed and commercialized with Pfizer. It is used to reduce thromboembolic risk in several cardiovascular settings, including atrial fibrillation, and is one of BMS's largest commercial products.

• OpdivoOncology immunotherapy2014

  Nivolumab is a PD-1 immune checkpoint inhibitor. By helping restore T-cell activity against tumors, it is used across multiple cancer indications and is often studied or prescribed in combination with other oncology medicines.

• RevlimidHematology and oncology

  Lenalidomide is an immunomodulatory medicine used in conditions including multiple myeloma and certain myelodysplastic syndromes. It entered the BMS portfolio through the Celgene acquisition and remains a major hematology product.

• OrenciaImmunology

  Abatacept is an immune-modulating therapy used for autoimmune diseases including rheumatoid arthritis. It reduces T-cell activation and represents one of BMS's established immunology franchises.

• PomalystHematology and oncology

  Pomalidomide is an immunomodulatory anticancer medicine used primarily in multiple myeloma and also associated with treatment of AIDS-related Kaposi sarcoma. It is marketed as Imnovid in some markets.

• YervoyOncology immunotherapy

  Ipilimumab is a CTLA-4 immune checkpoint inhibitor used in cancer treatment. It is an important component of BMS's immuno-oncology portfolio and is used in selected monotherapy and combination regimens.

• ReblozylHematology

  Luspatercept is used to treat anemia associated with beta thalassemia and myelodysplastic syndromes. Its regulatory label has expanded over time, including use in selected lower-risk myelodysplastic-syndrome patients.

• CobenfyNeuroscience and psychiatry2024

  Cobenfy is the commercial name for the xanomeline and trospium combination acquired through Karuna Therapeutics. It was approved in the United States for adults with schizophrenia and uses a muscarinic mechanism distinct from conventional dopamine-receptor antipsychotics.

• Sal HepaticaConsumer healthcare

  Sal Hepatica was an early nationally recognized Bristol-Myers product, marketed as a laxative mineral-salt preparation. It is no longer a current BMS product.

• IpanaOral care1901

  Ipana was a toothpaste brand introduced by Bristol-Myers in the early twentieth century. It formed part of the company's historic consumer-products portfolio and is no longer produced by BMS.

• 2023Cellares cell-therapy manufacturing partnership

  United States · International

  BMS partnered with Cellares to explore robotic and automated production of CAR-T therapies, seeking to improve manufacturing consistency, capacity, and speed.

  Outcome. Partnership announced; subsequent commercial outcome is not established in the supplied material.

  Source
• 2022Owkin clinical-research collaboration

  France · International

  BMS invested in French artificial-intelligence company Owkin and planned collaboration on more precise and efficient clinical-trial design, initially in cardiovascular disease.

  Outcome. Collaboration announced; long-term campaign results are not specified in the supplied material.

  Source

• 2024Acquisition of Karuna TherapeuticsM&A

  BMS aimed to add a late-stage neuroscience asset and diversify beyond its core oncology and immunology franchises.

  What changed. BMS acquired Karuna and its lead muscarinic program, subsequently commercialized as Cobenfy.

  Aftermath. The transaction enabled BMS to enter the modern schizophrenia-treatment market with a novel mechanism.

  Acquisition value. $14 billion (2024)

  Source
• 2020Acquisition of MyoKardiaM&A

  BMS sought to reinforce cardiovascular medicine alongside its established oncology, immunology, and hematology businesses.

  What changed. The company acquired MyoKardia and obtained mavacamten and related cardiovascular development programs.

  Aftermath. The acquisition broadened BMS's cardiovascular pipeline and commercial ambitions.

  Acquisition value. $13.1 billion (2020)

  Source
• 2019Acquisition of CelgeneM&A

  BMS needed to strengthen its pipeline and expand its oncology and hematology franchises, including in response to competitive pressure in immuno-oncology.

  What changed. BMS agreed to acquire Celgene; regulatory clearance required Amgen to acquire Otezla from Celgene.

  Aftermath. The transaction materially expanded BMS's oncology and hematology portfolio and became the company's defining strategic combination of the period.

  Transaction value. Approximately $74 billion in equity value, or approximately $95 billion including debt (2019 announcement and transaction)

  Source
• 2007Shift toward a specialty biopharmaceutical modelStrategy

  BMS sought to reduce the complexity of its diversified healthcare structure and focus resources on innovative prescription medicines and biologic products.

  What changed. The company pursued alliances, acquisitions, consumer-business divestitures, manufacturing consolidation, productivity programs, and workforce reductions.

  Aftermath. The strategy established the structure and therapeutic focus of the modern BMS.

  Source

• 2006Plavix distribution and channel-stuffing controversyControversy

  The FBI searched BMS corporate offices in connection with allegations involving Plavix distribution, channel stuffing, and generic competition. A court-appointed monitor urged removal of CEO Peter Dolan, who stepped down. The deferred-prosecution agreement ended in 2007 without further Department of Justice action on the matters covered by it.

  Source

• 2024BMS acquired Mirati Therapeutics

  The transaction added Mirati's targeted oncology capabilities and cancer medicines to BMS's research and commercial portfolio.

  M&A
  Source
• 2024BMS acquired Karuna Therapeutics

  The acquisition brought KarXT, later marketed as Cobenfy, into BMS and expanded the company into innovative treatments for schizophrenia.

  M&A
  Source
• 2024FDA approved Cobenfy for schizophrenia

  Cobenfy became the first approved treatment in decades for schizophrenia based on a new muscarinic mechanism rather than conventional dopamine receptor blockade.

  Product launchProduct generationRegulation
  Source
• 2022BMS acquired Turning Point Therapeutics

  The purchase expanded the company's targeted-cancer portfolio, particularly through repotrectinib.

  M&A
  Source
• 2020BMS acquired MyoKardia for cardiovascular drug mavacamten

  The acquisition added mavacamten and related cardiovascular programs, broadening BMS beyond its established oncology, immunology, and hematology franchises.

  M&A
  Source
• 2019Bristol Myers Squibb agreed to acquire Celgene

  The transaction substantially expanded BMS's oncology and hematology portfolio and was designed to replenish the company's pipeline. Regulatory approval required the sale of Otezla to Amgen.

  M&A
  Source
• 2014Opdivo received U.S. approval for advanced melanoma

  The FDA approved nivolumab, marketed as Opdivo, for certain patients with unresectable or treatment-resistant skin cancer, strengthening BMS's immuno-oncology position.

  Product launchProduct generation
  Source
• 2009Bristol Myers Squibb completed its strategic shift toward specialty biopharmaceuticals

  The company launched restructuring, cost-reduction, manufacturing consolidation, and workforce changes to focus more tightly on prescription pharmaceuticals and biologic products.

  Other
  Source

1. Bristol Myers Squibb
2. Bristol Myers Squibb official website